14 Best Undervalued Stocks to Buy Under $50

Page 5 of 13

9. GSK plc (NYSE:GSK)

Stock Price: $47.10

​Forward P/E: 10.50

Number of Hedge Fund Holders: 36

GSK plc (NYSE:GSK) is one of the best undervalued stocks to buy under $50. Deutsche Bank analyst Emmanuel Papadakis released a rating update for GSK plc (NYSE:GSK), maintaining a Hold rating on the stock with a £16 price target on November 4.

GSK plc (NYSE:GSK) recently released its fiscal Q3 earnings on October 29, reporting that vaccines, specialty medicines, and general medicines drove sales, profit, and earnings growth. Total sales for the quarter were £8.5 billion, up 7% AER and 8% CER. Sales in Specialty Medicines rose 16% to £3.4 billion, those in Respiratory, Immunology & Inflammation rose 15% to £1.0 billion, while Oncology and HIV sales grew 39% and 12%, respectively. Vaccine sales in fiscal Q3 2025 rose 2% to £2.7 billion.

Management further reported that core operating profit rose 11% and core EPS experienced a 14% growth, reflecting the above mentioned growth in Specialty Medicines and Vaccines, higher royalty income, and disciplined increased investment in R&D portfolio progression in Oncology and Vaccines.

GlaxoSmithKline, GSK plc (NYSE:GSK) upgraded its 2025 guidance, and now expects core EPS growth of between 10% to 12% compared to the previous range of between 6% to 8%. It also expects core operating profit growth of between 9% to 11% compared to the previous 6% to 8%.

Formerly known as GlaxoSmithKline, GSK plc (NYSE:GSK) is a global healthcare and biopharmaceutical corporation that develops and distributes a range of vaccines, medications, and consumer health items. It is based in the United Kingdom and has over 20 vaccines in its portfolio, positioning it as a leader in vaccines, immunology, and respiratory therapies. The company also develops cancer treatments for multiple myeloma, ovarian cancer, and endometrial cancer, in addition to other drugs.

Page 5 of 13